價格 | ¥413 | ¥980 | ¥1490 |
包裝 | 1mg | 5mg | 10mg |
最小起訂量 | 1mg |
發(fā)貨地 | 上海 |
更新日期 | 2024-12-12 |
中文名稱:化合物 Belotecan hydrochloride | 英文名稱:Belotecan hydrochloride |
CAS:213819-48-8 | 品牌: TargetMol |
產(chǎn)地: 美國 | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
純度規(guī)格: ≥95% | 產(chǎn)品類別: 抑制劑 |
貨號: T7551 |
名稱 | Belotecan hydrochloride |
描述 | Belotecan hydrochloride (CKD-602) is a synthetic water-soluble camptothecin derivative and topoisomerase I inhibitor with potential antitumor activity |
細(xì)胞實驗 | Cells at a density of 2×10^4 cells/well in 100 μl RPMI with 10% FBS were added to the wells of a 96-well plate.?The cells were treated with different concentrations (0.01, 0.1, 0.5, 1, 5 and 10 μg/ml) of CKD-602 for 24, 48 and 72 h. Control samples of each cell line were treated with medium only.?For the viability assay, 20 μl/well CellTiter 96AQueous One Solution Reagent (MTS) was added.?After 1 h incubation at 37°C in a humidified atmosphere of 5% CO2, the absorbance at 490 nm was recorded using an ELISA plate reader ?The assay was performed in triplicate with three independent experiments for each condition.?The data from the treatment groups were normalized to those of the control samples and are presented as the mean ±standard error of the mean.?The half maximal (50%) inhibitory concentration (IC50) values were calculated from the dose-response curve[1]. |
體外活性 | Belotecan hydrochloride(CKD-602) 在所有細(xì)胞系中的效果顯示出顯著的時間和劑量依賴性細(xì)胞毒作用。在治療72小時后,YD-8、YD-9和YD-38細(xì)胞的細(xì)胞活性IC50值分別為2.4 μg/ml、0.18 μg/ml和0.05 μg/ml[1]。 |
存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 10 mg/mL (21.28 mM), Sonication is recommended. |
關(guān)鍵字 | Belotecan | Topoisomerase | Inhibitor | Belotecan hydrochloride | CKD602 | Belotecan Hydrochloride | CKD 602 | inhibit |
相關(guān)產(chǎn)品 | Prulifloxacin | Exatecan Mesylate | Norfloxacin | Ciprofloxacin | Berberine chloride | Etoposide | Levofloxacin hydrochloride | Ciprofloxacin monohydrochloride | EIDD-1931 | Pefloxacin Mesylate | Flumequine | Enoxacin |
相關(guān)庫 | 抑制劑庫 | 抗癌活性化合物庫 | 抗癌上市藥物庫 | 經(jīng)典已知活性庫 | 已知活性化合物庫 | FDA上市及藥典收錄分子庫 | 抗衰老化合物庫 | 藥物功能重定位化合物庫 | 抗癌臨床化合物庫 | 抗癌藥物庫 |
成立日期 | 2013-04-18 (12年) | 注冊資本 | 566.265100萬人民幣 |
員工人數(shù) | 100-500人 | 年營業(yè)額 | ¥ 1億以上 |
主營行業(yè) | 天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù) | 經(jīng)營模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
---|---|---|---|---|
詢價 |
VIP3年
|
河南威梯希化工科技有限公司
|
2025-01-18 | |
詢價 |
VIP9年
|
武漢維斯?fàn)柭锕こ逃邢薰?/div>
|
2025-01-18 | |
詢價 |
VIP9年
|
上海率典醫(yī)藥科技有限公司
|
2025-01-05 | |
詢價 |
VIP2年
|
陜西締都新材料有限公司
|
2024-12-18 | |
¥392.90 |
VIP2年
|
上海阿拉丁生化科技股份有限公司
|
2024-11-29 |